Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. 2007

Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
United States Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Intramural Research Program, Cellular Neurobiology Branch, Electrophysiology Research Unit, Baltimore, Maryland 21224, USA.

Memory deficits produced by marijuana arise partly via interaction of the psychoactive component, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), with cannabinoid receptors in the hippocampus. Although cannabinoids acutely reduce glutamate release and block hippocampal long-term potentiation (LTP), a potential substrate for learning and memory, the consequences of prolonged exposure to Delta(9)-THC for hippocampal function are poorly understood. Rats were injected with Delta(9)-THC (10 mg/kg, i.p., q.d.) for 1, 3, or 7 d, and electrophysiological recordings were performed in hippocampal slices 1d after the final injection. At this time, Delta(9)-THC was undetectable in hippocampus using liquid chromatography-mass spectrometry (LC-MS). Hippocampal LTP generated using high-frequency (HFS) or theta burst stimulation was not observed in brain slices from the 7-d Delta(9)-THC-treated animals. Delta(9)-THC also blocked HFS-LTP after 3 d, but not 1 d of treatment. The complete blockade of LTP persisted for 3 d after the last Delta(9)-THC injection, and full reversal of the LTP deficit was not observed up to 14 d following Delta(9)-THC withdrawal. The cannabinoid antagonist AM251 (2 mg/kg), administered before each Delta(9)-THC injection prevented the blockade of LTP, and 7-d treatment with AM251 alone significantly increased the level of LTP. Chronic Delta(9)-THC also produced tolerance to the inhibition of synaptic GABA, but not glutamate release by the agonist WIN55,212-2. These data define consequences of repeated Delta(9)-THC exposure for synaptic plasticity in the hippocampus that may help explain memory impairments in humans following chronic marijuana use.

UI MeSH Term Description Entries
D008297 Male Males
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D010880 Piperidines A family of hexahydropyridines.
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002186 Cannabinoids Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. Cannabinoid
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical

Related Publications

Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
July 1998, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
December 2006, The Journal of pharmacology and experimental therapeutics,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
March 2017, Addiction biology,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
January 2002, Hippocampus,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
August 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
November 1976, Psychopharmacology,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
January 2003, European journal of pharmacology,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
January 2007, Brain research,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
January 1995, Hippocampus,
Alexander F Hoffman, and Murat Oz, and Ruiqin Yang, and Aron H Lichtman, and Carl R Lupica
February 1993, Experimental neurology,
Copied contents to your clipboard!